CN113874009A - 治疗与s1p1受体有关的病况的方法 - Google Patents

治疗与s1p1受体有关的病况的方法 Download PDF

Info

Publication number
CN113874009A
CN113874009A CN202080018255.4A CN202080018255A CN113874009A CN 113874009 A CN113874009 A CN 113874009A CN 202080018255 A CN202080018255 A CN 202080018255A CN 113874009 A CN113874009 A CN 113874009A
Authority
CN
China
Prior art keywords
compound
individual
solvate
hydrate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080018255.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·纳伊克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69467760&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113874009(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Priority to CN202411067321.3A priority Critical patent/CN118976023A/zh
Publication of CN113874009A publication Critical patent/CN113874009A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CN202080018255.4A 2019-01-08 2020-01-08 治疗与s1p1受体有关的病况的方法 Pending CN113874009A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411067321.3A CN118976023A (zh) 2019-01-08 2020-01-08 治疗与s1p1受体有关的病况的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789937P 2019-01-08 2019-01-08
US62/789,937 2019-01-08
PCT/US2020/012783 WO2020146529A1 (en) 2019-01-08 2020-01-08 Methods of treating conditions related to the s1p1 receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411067321.3A Division CN118976023A (zh) 2019-01-08 2020-01-08 治疗与s1p1受体有关的病况的方法

Publications (1)

Publication Number Publication Date
CN113874009A true CN113874009A (zh) 2021-12-31

Family

ID=69467760

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080018255.4A Pending CN113874009A (zh) 2019-01-08 2020-01-08 治疗与s1p1受体有关的病况的方法
CN202411067321.3A Pending CN118976023A (zh) 2019-01-08 2020-01-08 治疗与s1p1受体有关的病况的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411067321.3A Pending CN118976023A (zh) 2019-01-08 2020-01-08 治疗与s1p1受体有关的病况的方法

Country Status (9)

Country Link
US (1) US20220142977A1 (https=)
EP (1) EP3908276B1 (https=)
JP (1) JP2022516662A (https=)
CN (2) CN113874009A (https=)
AU (1) AU2020206700A1 (https=)
CA (1) CA3124701A1 (https=)
IL (1) IL284114A (https=)
MX (1) MX2021008263A (https=)
WO (1) WO2020146529A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
MX2019009843A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
JP7265620B2 (ja) * 2018-10-03 2023-04-26 アリーナ ファーマシューティカルズ， インコーポレイテッド 強皮症の治療のための方法
CN113874009A (zh) 2019-01-08 2021-12-31 艾尼纳制药公司 治疗与s1p1受体有关的病况的方法
WO2025177319A2 (en) * 2024-02-22 2025-08-28 Msn Laboratories Private Limited, R&D Center Solid state forms of L-Arginine, (3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopent[b]indole-3-acetate and processes for preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112075A1 (en) * 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
HRP20160890T1 (hr) * 2008-08-27 2016-09-23 Arena Pharmaceuticals, Inc. Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
MX367097B (es) * 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬
CN113874009A (zh) 2019-01-08 2021-12-31 艾尼纳制药公司 治疗与s1p1受体有关的病况的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112075A1 (en) * 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN107405332A (zh) * 2015-01-06 2017-11-28 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
W J SANDBORN: "A randomized, double-blind, placebo-controlled trial of a selective, oral sphingosine 1-phosphate receptor modulator, etrasimod(APD334), in moderate to severe ulcerative colitis: Results from the oasis study", 26TH UNITED EUR GASTROENTEROL WEEK, vol. 113, pages 327 *

Also Published As

Publication number Publication date
JP2022516662A (ja) 2022-03-01
MX2021008263A (es) 2021-10-13
US20220142977A1 (en) 2022-05-12
AU2020206700A1 (en) 2021-07-15
KR20210113298A (ko) 2021-09-15
CA3124701A1 (en) 2020-07-16
EP3908276A1 (en) 2021-11-17
IL284114A (en) 2021-08-31
EP3908276B1 (en) 2025-06-11
CN118976023A (zh) 2024-11-19
WO2020146529A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
CN113874009A (zh) 治疗与s1p1受体有关的病况的方法
JP7219732B2 (ja) Ｓ１ｐ１受容体に関連する状態の処置方法
JP2025024035A (ja) Ｓ１ｐ１受容体に関連する状態を治療する方法
ES2987794T3 (es) Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
TWI646960B (zh) 慢性腎臟病之進展抑制或改善用製劑
CN119215038A (zh) mGluR5拮抗剂用于治疗阿片类物质镇痛耐受性的用途
KR102958419B1 (ko) S1p₁ 수용체와 관련된 병태의 치료 방법
HK40116740A (zh) 治疗与s1p1受体有关的病况的方法
CN115038438A (zh) 治疗与s1p1受体相关的病症的方法
HK40116488A (zh) 治疗与s1p1受体有关的病况的方法
HK40063670B (en) Methods of treating conditions related to the s1p1 receptor
HK40063670A (en) Methods of treating conditions related to the s1p1 receptor
KR20200021479A (ko) 페마피브레이트를 함유하는 의약
TWI855501B (zh) 治療方法
EP4326266A1 (en) Methods of treating b-cell lymphoma using combination therapy
KR20240013810A (ko) 간 손상을 갖는 개체에의 화합물의 투여

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20211231